These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22993933)

  • 1. [Investigation of structural characteristics of initial substances of ibuprofen and micronization impact].
    Lobanov NN; Khuchua NS; Obidchenko IuA; Abramovich RA
    Antibiot Khimioter; 2012; 57(3-4):3-8. PubMed ID: 22993933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the optical purity of ibuprofen using X-ray powder diffraction.
    Stahly GP; McKenzie AT; Andres MC; Russell CA; Byrn SR; Johnson P
    J Pharm Sci; 1997 Aug; 86(8):970-1. PubMed ID: 9269877
    [No Abstract]   [Full Text] [Related]  

  • 3. Preparation, characterization, and evaluation of physicochemical properties of different crystalline forms of ibuprofen.
    Khan GM; Jiabi Z
    Drug Dev Ind Pharm; 1998 May; 24(5):463-71. PubMed ID: 9876609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial salt screening procedures for manufacturing ibuprofen.
    Lee T; Wang YW
    Drug Dev Ind Pharm; 2009 May; 35(5):555-67. PubMed ID: 19005918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a new crystalline phase of racemic Ibuprofen.
    Dudognon E; Danède F; Descamps M; Correia NT
    Pharm Res; 2008 Dec; 25(12):2853-8. PubMed ID: 18563538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous micronization and surface modification for improvement of flow and dissolution of drug particles.
    Han X; Ghoroi C; To D; Chen Y; Davé R
    Int J Pharm; 2011 Aug; 415(1-2):185-95. PubMed ID: 21664954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical stability of solid dispersions of enantiomeric or racemic ibuprofen in stearic acid.
    Corvis Y; Négrier P; Espeau P
    J Pharm Sci; 2011 Dec; 100(12):5235-43. PubMed ID: 21905027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical aspects of dexibuprofen and racemic ibuprofen.
    Leising G; Resel R; Stelzer F; Tasch S; Lanziner A; Hantich G
    J Clin Pharmacol; 1996 Dec; 36(12 Suppl):3S-6S. PubMed ID: 9013377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibuprofen agglomerates preparation by phase separation.
    Jbilou M; Ettabia A; Guyot-Hermann AM; Guyot JC
    Drug Dev Ind Pharm; 1999 Mar; 25(3):297-305. PubMed ID: 10071822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comminution of ibuprofen to produce nano-particles for rapid dissolution.
    Plakkot S; de Matas M; York P; Saunders M; Sulaiman B
    Int J Pharm; 2011 Aug; 415(1-2):307-14. PubMed ID: 21683776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel ibuprofen-loaded solid dispersion with enhanced bioavailability using cycloamylose.
    Baek HH; Kim DH; Kwon SY; Rho SJ; Kim DW; Choi HG; Kim YR; Yong CS
    Arch Pharm Res; 2012 Mar; 35(4):683-9. PubMed ID: 22553061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similarity in structures of racemic and enantiomeric ibuprofen sodium dihydrates.
    Zhang Y; Grant DJ
    Acta Crystallogr C; 2005 Sep; 61(Pt 9):m435-8. PubMed ID: 16143769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of in situ granulation and temperature quenching on crystal habit and micromeritic properties of ibuprofen-cationic dextran conjugate crystanules.
    Abioye AO; Kola-Mustapha A; Ruparelia K
    Int J Pharm; 2014 Feb; 462(1-2):83-102. PubMed ID: 24378327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism on leflunomide: stability and crystal structures.
    Vega D; Petragalli A; Fernández D; Ellena JA
    J Pharm Sci; 2006 May; 95(5):1075-83. PubMed ID: 16570307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural properties of so-called NSAID-phospholipid-complexes.
    Hüsch J; Dutagaci B; Glaubitz C; Geppert T; Schneider G; Harms M; Müller-Goymann CC; Fink L; Schmidt MU; Setzer C; Zirkel J; Rebmann H; Schubert-Zsilavecz M; Abdel-Tawab M
    Eur J Pharm Sci; 2011 Sep; 44(1-2):103-16. PubMed ID: 21726639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process.
    Chun NH; Wang IC; Lee MJ; Jung YT; Lee S; Kim WS; Choi GJ
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):854-61. PubMed ID: 23454054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous quantification of an enantiomer and the racemic compound of ibuprofen by X-ray powder diffractometry.
    Phadnis NV; Suryanarayanan R
    Pharm Res; 1997 Sep; 14(9):1176-80. PubMed ID: 9327444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of ibuprofen crystallized under various conditions: a comparative study.
    Rasenack N; Müller BW
    Drug Dev Ind Pharm; 2002 Oct; 28(9):1077-89. PubMed ID: 12455467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ab initio structure determination of phase II of racemic ibuprofen by X-ray powder diffraction.
    Derollez P; Dudognon E; Affouard F; Danède F; Correia NT; Descamps M
    Acta Crystallogr B; 2010 Feb; 66(Pt 1):76-80. PubMed ID: 20101086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilisation of amorphous ibuprofen in Upsalite, a mesoporous magnesium carbonate, as an approach to increasing the aqueous solubility of poorly soluble drugs.
    Zhang P; Forsgren J; Strømme M
    Int J Pharm; 2014 Sep; 472(1-2):185-91. PubMed ID: 24950364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.